Sugi Predict

Sugi Predict / Compounds / SCHEMBL1551352

SCHEMBL1551352

SCHEMBL1551352

COc1ccc(-c2ncccc2N)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.65
▸ ALDH1A1 P00352 4/20 0.65
▸ HPGD P15428 1/20 0.65
▸ CLK4 Q9HAZ1 1/20 0.56
▸ KCNA5 P22460 1/20 0.49
▸ SYK P43405 1/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ DYRK1A Q13627 1/20 0.49
▸ NPC1 O15118 4/20 0.48
▸ RAB9A P51151 4/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ ADORA2A P29274 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ AURKA O14965 1/20 0.45
▸ CCNB2 O95067 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610433 1.00 KDM4E (0.65) KDM4EALDH1A1HPGDCLK4KCNA5
SCHEMBL28418085 0.84 ADORA2A (0.48) KDM4EALDH1A1HPGDCLK4SYK
SCHEMBL27866855 0.81 DYRK1A (0.60) KDM4EALDH1A1HPGDCLK4KCNA5
SCHEMBL7113110 0.80 KDM4E (0.67) KDM4EALDH1A1HPGDCLK4KCNA5
SCHEMBL935169 0.80 ALDH1A1 (0.67) KDM4EALDH1A1HPGDCLK4KCNA5
SCHEMBL4436880 0.79 KMT2A (0.49) KDM4EALDH1A1HPGDSYKKMT2A
SCHEMBL1003068 0.79 DYRK1A (0.53) KDM4EALDH1A1HPGDCLK4KMT2A
SCHEMBL5313883 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDCLK4KCNA5
SCHEMBL12521001 0.79 KDM4E (0.65) KDM4EALDH1A1HPGDCLK4KCNA5
SCHEMBL5330253 0.79 KDM4E (0.65) KDM4EALDH1A1HPGDCLK4KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 — — US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 — — US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 — — CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 — — CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 — — US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 — — US disclosed
CN-111320575-B Pyridine-2-aryl-3-sulfonamide compound and synthesis method and application thereof 浙江大学 2022-04-05 — — CN disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 — — US disclosed
CN-111320575-A Pyridine-2-aryl-3-sulfonamide compound and synthesis method and application thereof 浙江大学 2020-06-23 — — CN disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 — — EP disclosed
US-20130005710-A1 AMINOPYRIDINE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-03 — — US disclosed
US-20130005710-A1 AMINOPYRIDINE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-03 — — US disclosed
US-20130005710-A1 AMINOPYRIDINE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-03 — — US disclosed
EP-2313391-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-12-26 — — EP disclosed
EP-2502909-A1 AMINOPYRIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2012-09-26 — — EP disclosed
WO-2011062194-A1 AMINOPYRIDINE DERIVATIVE 武田薬品工業株式会社 (JP) 2011-05-26 — — WO disclosed
EP-2313391-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2011-04-27 — — EP disclosed
WO-2009156339-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-12-30 — — WO disclosed
US-20060041144-A1 Phenylpyridine compound and fungicidal compostion containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-02-23 — — US disclosed
EP-1541557-A1 PHENYLPYRIDINE COMPOUND AND BACTERICIDAL COMPOSITION CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2005-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 KDM4E 1773/4885ALDH1A1 1183/4885HPGD 1657/4885
US-20130005710-A1 AMINOPYRIDINE DERIVATIVE DCX, NR0B1, NR4A1 KDM4E 832/4885ALDH1A1 274/4885HPGD 1076/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT KDM4E 1119/4885ALDH1A1 1681/4885HPGD 361/4885
US-20060041144-A1 Phenylpyridine compound and fungicidal compostion containing the same CBR3, CYP1A1, PAH KDM4E 351/4885ALDH1A1 2020/4885HPGD 2638/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS KDM4E 1078/4885ALDH1A1 1490/4885HPGD 313/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 KDM4E 1254/4885ALDH1A1 1415/4885HPGD 812/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT KDM4E 1160/4885ALDH1A1 1184/4885HPGD 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.